The Islandic company Kerecis has developed Omega3 Wound Plus, a novel wound treatment comprising a processed, acellular, Omega-3-rich fish-skin matrix that favors healing, reduces inflammation and prevents infection. A two-year clinical trial was launched in 2020 in France, Germany, Italy and Sweden to test the treatment in the setting of deep lower limb wounds including diabetic foot ulcers. In France, the trial involves more than 200 patients in six care facilities including the South Île-de-France Medical Center (CHSF).
Dr. Dardari’s Diabetic Foot Unit at the CHSF currently counts the greatest number of patients enrolled in France for that study. There, about 40 patients have been treated with the fish-skin matrix since July 2020. Dr. Dardari and his team had the pleasure of welcoming a Kerecis delegation to observe the initial study results.
The Study and Research Center for the Intensification of Diabetes Treatment (CERITD) located at Genopole is working on the cost-effectiveness aspects of this 100% natural treatment, which may reduce the use of analgesics and antibiotics, and furthermore enable at-home follow-up. Indeed, a goal of the study is to obtain reimbursement by the French healthcare system for the treatment, which already has European market authorization.